FrancophonIA/ELRC3.0 huggingface dataset:
English: Adults and adolescents (weighing at least 40kg) The recommended dose of Triumeq in adults and adolescents is one tablet once daily.
Slovenian: Odrasli in mladostniki (ki tehtajo vsaj 40 kg) Priporočeni odmerek zdravila Triumeq za odrasle in mladostnike je ena tableta enkrat dnevno.
English: Available toxicological data in animals have shown excretion of dolutegravir in milk.
Slovenian: Razpoložljivi toksikološki podatki na živalih kažejo, da se dolutegravir izloča v mleko.
English: What Triumeq is and what it is used for
Slovenian: Kaj je zdravilo Triumeq in za kaj ga uporabljamo
English: It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Slovenian: Priporočljivo je, da ženske, okužene z virusom HIV, ne dojijo pod nobenim pogojem, da ne bi prišlo do prenosa virusa HIV.
English: The most common symptoms are: fever (high temperature) and skin rash.
Slovenian: Najpogostejša simptoma sta: povišana telesna temperatura (vročina) in izpuščaj na koži.
English: Talk to your doctor before you start taking it again.
Slovenian: Posvetujte se z zdravnikom, preden ga začnete ponovno jemati.
English: Therapy should be prescribed by a physician experienced in the management of HIV infection.
Slovenian: Zdravljenje mora predpisati zdravnik z izkušnjami pri zdravljenju okužbe z virusom HIV.
English: Those studied were mainly antiretroviral experienced patients.
Slovenian: Bolniki, ki so bili vključeni v študijo, so večinoma že imeli izkušnje s protiretrovirusnimi zdravili.
English: Overall the available data from observational cohorts and from randomised trials show some inconsistency so can neither confirm nor refute a causal relationship between abacavir treatment and the risk of myocardial infarction.
Slovenian: V celoti dostopni podatki iz opazovalnih skupin in randomiziranih študij kažejo nekaj neskladnosti in ne morejo niti potrditi niti ovreči vzročne povezave med zdravljenjem z abakavirjem in tveganjem za miokardni infarkt.
English: Hypersensitivity reactions can start at any time during treatment with Triumeq, but are more likely during the first 6 weeks of treatment.
Slovenian: Preobčutljivostne reakcije se lahko pojavijo kadar koli med zdravljenjem z zdravilom Triumeq, a so verjetnejše v prvih 6 tednih zdravljenja.
English: In case of any symptoms suggesting hypersensitivity reactions, contact your doctor IMMEDIATELY.
Slovenian: V primeru kakršnih koli simptomov, ki kažejo na preobčutljivostno reakcijo, se TAKOJ posvetujte z zdravnikom.
English: Very rarely, patients who have taken medicines containing abacavir in the past without any symptoms of hypersensitivity have developed a hypersensitivity reaction when they start taking these medicines again.
Slovenian: Zelo redko se je pri bolnikih, ki so v preteklosti že jemali zdravila, ki vsebujejo abakavir, in ob tem niso imeli nobenih simptomov preobčutljivosti, preobčutljivostna reakcija pojavila, ko so začeli ponovno jemati ta zdravila.
English: If the next dose is due within 4 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
Slovenian: Če je čas do naslednjega odmerka do 4 ure, bolnik ne sme vzeti pozabljenega odmerka in preprosto nadaljuje z jemanjem po ustaljenem urniku.
English: The adjusted difference in proportion and 95% CI [ABC/DTG/3TC vs current ART] were 3.4%; 95% CI: [-9.1, 2.4].
Slovenian: Korigirana razlika v deležih in 95 % IZ [ABC/DTG/3TC v primerjavi s trenutnim ART] sta bila 3,4 % in 95 % IZ: [-9,1, 2,4].
English: M184V mutants display greatly reduced susceptibility to lamivudine and show diminished viral replicative capacity in vitro.
Slovenian: Mutanti M184V kažejo močno zmanjšano občutljivost na lamivudin in zmanjšano sposobnost virusne replikacije in vitro.
English: Abacavir and lamivudine may inhibit cellular DNA replication and abacavir has been shown to be carcinogenic in animal models (see section 5.3).
Slovenian: Abakavir in lamivudin lahko zavirata replikacijo celične DNK, abakavir pa se je v študijah na živalskih modelih izkazal za karcinogenega (glejte poglavje 5.3).
English: Other key symptoms include gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise.
Slovenian: Drugi ključni simptomi vključujejo gastrointestinalne, respiratorne ali sistemske simptome, kot sta letargija in splošno slabo počutje.
English: Some clinical findings also support a possible interaction between lamivudine and cladribine
Slovenian: Nekatere klinične ugotovitve potrjujejo tudi možno medsebojno delovanje med lamivudinom in kladribinom.
English: Therefore, patients with any of these symptoms should be carefully evaluated for the presence of this hypersensitivity (see section 4.4).
Slovenian: Zato je potrebno pri bolnikih s katerim koli od teh simptomov skrbno presoditi, ali gre za preobčutljivost (glejte poglavje 4.4).
English: Of these four, two subjects had a unique R263K integrase substitution, with a maximum fold change of 1.93, one subject had a polymorphic V151V/I integrase substitution, with maximum fold change of 0.92, and one subject had pre-existing integrase mutations and is assumed to have been integrase experienced or infected with integrase resistant virus by transmission.
Slovenian: Od teh štirih sta dva preiskovanca imela edinstveno substitucijo integraze R263K, z maksimalno vrednostjo spremembe občutljivosti 1,93, en preiskovanec je imel polimorfno substitucijo integraze V151V/I z maksimalno vrednostjo spremembe občutljivosti 0,92, en preiskovanec pa je imel že obstoječe mutacije integraze in se predpostavlja, da je predhodno že dobival zdravila iz skupine zaviralcev integraz ali je bil preko prenosa okužen z virusom, odpornim na integrazo.
English: Medicinal products that induce those enzymes or transporters may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir (see Table 1).
Slovenian: Zdravila, ki inducirajo te encime ali prenašalce, lahko znižajo plazemske koncentracije dolutegravirja in zmanjšajo njegov terapevtski učinek (glejte Preglednico 1).
English: • skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)
Slovenian: • izpuščaj na koži, ki lahko oblikuje mehurje in daje videz majhnih tarč (temnih osrednjih točk, ki jih obdaja svetlejši predel, obdan s temnim robom) (multiformni eritem)
English: Triumeq is not recommended for use in combination with emtricitabine containing products, since both lamivudine (in Triumeq) and emtricitabine are cytidine analogues (i.e. risk for intracellular interactions, (see section 4.4))
Slovenian: Zdravila Triumeq ni priporočljivo uporabljati v kombinaciji z zdravili, ki vsebujejo emtricitabin, ker sta tako lamivudin (v zdravilu Triumeq) kot tudi emtricitabin analoga citidina (tj. tveganje za znotrajcelične interakcije, (glejte poglavje 4.4)).
English: Pharmacotherapeutic group: Antivirals for systemic use, antivirals for treatment of HIV infections, combinations.
Slovenian: Farmakoterapevtska skupina: Zdravila za sistemsko zdravljenje virusnih infekcij, zdravila za zdravljenje infekcij s HIV, kombinacije.
English: • breakdown of muscle tissue
Slovenian: • razpad mišičnega tkiva
English: In lactating rats that received a single oral dose of 50 mg/kg at 10 days postpartum, dolutegravir was detected in milk at concentrations typically higher than blood.
Slovenian: Pri doječih podganah, ki so dobile enkraten peroralen odmerek 50 mg/kg 10 dni po kotitvi, so bile ugotovljene koncentracije dolutegravirja v mleku značilno višje od tistih v krvi.
English: • aches and pains (especially in the hip, knee or shoulder)
Slovenian: • bolečine v sklepih (zlasti v kolku, kolenu ali rami)
English: You should have been tested for this gene before Triumeq was prescribed for you.
Slovenian: Testiranje za ta gen ste morali opraviti, preden vam je zdravnik predpisal zdravilo Triumeq.
English: The mean systemic clearance of lamivudine is approximately 0.32 l/h/kg, predominantly by renal clearance (> 70%) via the organic cationic transport system.
Slovenian: Srednja vrednost sistemskega očistka lamivudina je približno 0,32 l/h/kg, pri čemer glavni delež odpade na ledvični očistek (> 70%), ki poteka preko organskega kationskega transportnega sistema.
English: Risk of heart attack The possibility that abacavir increases the risk of having a heart attack cannot be excluded.
Slovenian: Možnosti, da abakavir poveča tveganje za srčni infarkt, ni mogoče izključiti.
English: Methadone/Abacavir (40 to 90mg once daily for 14 days/600mg single dose, then 600mg twice daily for 14 days)
Slovenian: Opioidi metadon/abakavir (40 do 90 mg enkrat na dan, 14 dni/enkratni odmerek 600 mg, nato 600 mg dvakrat na dan 14 dni)
English: African-American/African Heritage/Other Age (years)
Slovenian: Spol moški ženske Rasa belci Afroameričani/afriško poreklo/drugo Starost (leta)
English: These metabolites are excreted in the urine.
Slovenian: Ta presnovka se izločata z urinom.
English: Resistance in vivo: (dolutegravir)
Slovenian: Odpornost in vivo: (dolutegravir)
English: What you need to know before you take Triumeq 3.
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Triumeq 3.
English: Trimethoprim (an inhibitor of these drug transporters) has been shown to increase lamivudine plasma concentrations, however the resulting increase was not clinically significant (see Table 1).
Slovenian: Trimetoprim (zaviralec teh prenašalcev zdravil) poveča koncentracijo lamivudina v plazmi, vendar posledično povečanje ni bilo klinično pomembno (glejte preglednico 1).
English: Not everyone responds to treatment with Triumeq in the same way.
Slovenian: Na zdravilo Triumeq se ne odzovejo vsi bolniki enako.
English: SIDE 2 You should immediately contact your doctor if you think you are having a hypersensitivity reaction to Triumeq.
Slovenian: Takoj se morate posvetovati s svojim zdravnikom, če menite, da imate preobčutljivostno reakcijo na zdravilo Triumeq.
English: Although the aetiology is considered to be multifactorial (including corticosteroid use, bisphosphonates, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to CART.
Slovenian: Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, difosfonatov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so poročali o primerih osteonekroze zlasti pri bolnikih z napredovalo boleznijo HIV in/ali dolgotrajno izpostavljenostjo CART.
English: Oral contraceptives Ethinyl estradiol (EE) and Norgestromin (NGMN)/Dolutegravir
Slovenian: Peroralni kontraceptivi etinilestradiol (EE) in norelgestromin (NGMN) /dolutegravir
English: WOCBP who are taking Triumeq should use effective contraception throughout treatment.
Slovenian: Ženske v rodni dobi, ki jemljejo zdravilo Triumeq, morajo skozi celotno zdravljenje uporabljati učinkovito kontracepcijo.
English: After 24 weeks all remaining subjects switched to ABC/DTG/3TC FDC (Late Switch).
Slovenian: Po 24 tednih so vsi preostali preiskovanci prešli na ABC/DTG/3TC FDC (pozni prehod).
English: Dolutegravir, abacavir and lamivudine have been shown to inhibit replication of lab-strains and clinical isolates of HIV in a number of cell types, including transformed T cell lines, monocyte/macrophage derived lines and primary cultures of activated peripheral blood mononuclear cells (PMBCs) and monocyte/macrophages.
Slovenian: Dolutegravir, abakavir in lamivudin dokazano zavirajo replikacijo laboratorijskih sevov in kliničnih izolatov HIV v številnih vrstah celic, vključno s transformiranimi linijami celic T, linijami pridobljenih iz monocitov/makrofagov ter v primarnih kulturah aktiviranih mononuklearnih celic (PMBCs) iz periferne krvi in monociti/makrofagi.
English: Oral use Triumeq can be taken with or without food (see section 5.2).
Slovenian: Zdravilo Triumeq se lahko jemlje s hrano ali brez nje (glejte poglavje 5.2).
English: For patients receiving lamivudine 300 mg once daily, the terminal intracellular half-life of lamivudine-TP was 16 to 19 hours.
Slovenian: Pri bolnikih, ki so prejemali 300 mg lamivudina enkrat dnevno, je bil končni znotrajcelični razpolovni čas izločanja lamivudinaTP 16 do 19 ur.
English: In previously untreated patients receiving dolutegravir + 2 NRTIs in Phase IIb and Phase III, no development of resistance to the integrase class, or to the NRTI class was seen (n=876, follow-up of 48-96 weeks).
Slovenian: Pri predhodno nezdravljenih bolnikih, ki so prejemali dolutegravir + 2 NRTI v študijah faze IIb in faze III, niso opazili odpornosti na zdravila iz skupine zaviralcev integraz ali NRTI (n=876, spremljanje 48-96 tednov).
English: Dolutegravir is primarily metabolized via UGT1A1 with a minor CYP3A component (9.7% of total dose administered in a human mass balance study).
Slovenian: Dolutegravir se presnavlja predvsem preko glukoronidacije z UGT1A1 in v majhni meri s CYP3A (9,7% skupnega odmerka, uporabljenega v študiji človeške masne bilance).
English: In 100% human serum, the mean fold shift for dolutegravir activity was 75-fold, resulting in protein adjusted IC90 of 0.064 ug/mL.
Slovenian: V 100% humanem serumu je bil povprečni zasuk aktivnost dolutegravirja 75-kraten, zaradi česar je bil prirejen zasuk proteina IC90 0,064 ug/ml.
English: Preliminary data from a surveillance study has suggested an increased incidence of neural tube defects (0.9%) in mothers exposed to dolutegravir (a component of Triumeq) at the time of conception compared with mothers exposed to non-dolutegravir containing regimens (0.1%).
Slovenian: Predhodni podatki iz opazovalne študije so pokazali večjo incidenco okvar nevralne cevi (0,9 %) pri materah, ki so bile ob spočetju izpostavljene dolutegravirju (sestavina zdravila Triumeq), v primerjavi z materami, ki so bile izpostavljene režimom, ki niso vsebovali dolutegravirja (0,1 %).
English: In vitro, abacavir was an inhibitor of MATE1; the clinical consequences are not known.
Slovenian: In vitro je abakavir zaviral MATE1; klinične posledice tega niso znane.
English: Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.
Slovenian: Dolutegravir zavira integrazo HIV z vezavo na aktivno mesto integraze in blokira korak prenosa vgradnje sklopa retrovirusne deoksiribonukleinske kisline (DNK), ki je bistvenega pomena za replikacijski ciklus HIV.
English: Based on limited available data with the dolutegravir single entity used in combination with other antiretroviral agents to treat adolescents (12 to 17 years), there were no additional types of adverse reactions beyond those observed in the adult population.
Slovenian: Na podlagi omejenih razpoložljivih podatkov o uporabi dolutegravirja kot samostojne entitete v kombinaciji z drugimi protiretrovirusnimi učinkovinami za zdravljenje mladostnikov (starih od 12 do 17 let) ni bilo nobenih dodatnih neželenih učinkov poleg tistih, ki so jih zabeležili pri odraslih.
English: The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin (<35 g/L) as seen in subjects with moderate hepatic impairment.
Slovenian: Delež nevezanega dolutegravirja v plazmi se pri nizkih vrednostih serumskega albumina (<35 g/l) poveča, kar je opazno pri osebah z zmerno okvaro jeter.
English: • an increase in sugar (glucose) in the blood
Slovenian: • povišana vrednost sladkorja (glukoze) v krvi
English: Discontinued study/study drug due to adverse event or death‡
Slovenian: Izstop iz študije/študijskega zdravila zaradi neželenega učinka ali smrti‡
English: This combination may increase the risk for lactic acidosis in patients with moderate renal impairment (stage 3a creatinine clearance [CrCl] 45- 59 mL/min) and a cautious approach is recommended.
Slovenian: Ta kombinacija lahko pri bolnikih z zmerno okvaro ledvic (stadij 3a, očistek kreatinina 45-59 ml/min) poveča tveganje za laktacidozo, zato je priporočljiva previdnost.
English: Symptoms have included rash, constitutional findings, and sometimes, organ dysfunction, including severe liver reactions.
Slovenian: Simptomi so vključevali izpuščaj, sistemske pojave, včasih pa tudi motnje v delovanju organov, vključno s hudimi jetrnimi reakcijami.
English: The likelihood of metabolic drug interactions with lamivudine is low due to the small extent of hepatic metabolism (5-10%).
Slovenian: Verjetnost presnovnih interakcij z drugimi zdravili je majhna zaradi majhnega obsega jetrne presnove (od 5 do 10%).
English: Thirty-two percent of the total oral dose is excreted in the urine, represented by ether glucuronide of dolutegravir (18.9% of total dose), N-dealkylation metabolite (3.6% of total dose), and a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose).
Slovenian: Dvaintrideset odstotkov celotnega peroralnega odmerka se izloči z urinom, bodisi v obliki dolutegravirjevega glukuronida (18,9% celotnega odmerka), metabolita N-dealkilacije (3,6% celotnega odmerka) in metabolita, ki nastane z oksidacijo na benzilnem ogljiku (3,0% celotnega odmerka).
English: In a Phase I/II 48 week multicentre, open-label study (P1093/ING112578), the pharmacokinetic parameters, safety, tolerability and efficacy of dolutegravir was evaluated in combination regimens in HIV-1 infected infants, children and adolescents.
Slovenian: V 48-tedenski multicentrični, odprti študiji (P1093/ING112578) faze I/II so ocenjevali farmakokinetične parametre, varnost, prenašanje in učinkovitost dolutegravirja v kombiniranih terapevtskih shemah pri dojenčkih, otrocih in mladostnikih, okuženih z virusom HIV-1.
English: The safety and efficacy of Triumeq in children less than 12 years of age has not yet been established.
Slovenian: Varnost in učinkovitost zdravila Triumeq pri otrocih, mlajših od 12 let, še nista bili dokazani.
English: Response rates at 96 weeks were 82% for DTG+ABC/3TC and 75% for DRV/r+ABC/3TC.
Slovenian: Po 96 tednih je bil delež odziva za DTG+ABC/3TC 82% in 75 % za DRV/r+ABC/3TC.
English: No clinical data are available in patients with moderate or severe hepatic impairment, therefore the use of Triumeq is not recommended unless judged necessary.
Slovenian: Pri bolnikih z zmerno ali hudo jetrno okvaro ni kliničnih podatkov, zato uporaba zdravila Triumeq ni priporočljiva, razen če je nujno potrebna.
English: The film-coated tablets are provided in bottles containing 30 tablets.
Slovenian: Filmsko obložene tablete so na voljo v plastenkah, ki vsebujejo 30 tablet.
English: At 24 weeks, 16 of 23 (69%) adolescents (12 to 17 years of age) treated with dolutegravir once daily (35 mg n=4; 50 mg n=19) plus OBR achieved viral load less than 50 copies/mL.
Slovenian: Po 24 tednih je 16 od 23 (69%) mladostnikov (starih od 12 do 17 let), zdravljenih z dolutegravirjem enkrat na dan (35 mg n=4, 50 mg n=19) plus OBR, doseglo virusno obremenitev manj kot 50 kopij/ml.
English: You may also be told never again to take any other medicine containing dolutegravir.
Slovenian: Morda vam bo tudi naročeno, da ne smete nikoli več vzeti katerega koli drugega zdravila, ki vsebuje dolutegravir.
English: More than 1000 outcomes from second and third trimester exposure to dolutegravir in pregnant women indicate no evidence of increased risk of malformative and foeto/neonatal negative effects.
Slovenian: Več kot 1.000 primerov izpostavljenosti nosečnic v drugem in tretjem trimesečju ne navaja dokazov o povečanem tveganju za deformacije in negativne učinke na plod/novorojenčka.
English: If you take too many tablets of Triumeq, contact your doctor or pharmacist for advice.
Slovenian: Če ste vzeli preveč zdravila Triumeq, se posvetujte z zdravnikom ali farmacevtom.
English: If you take more Triumeq than you should
Slovenian: Če ste vzeli večji odmerek zdravila Triumeq, kot bi smeli
English: → Read the information ‘Other possible side effects of combination therapy for HIV' in Section 4 of this leaflet.
Slovenian: → Preberite odlomek »Drugi možni neželeni učinki kombiniranega zdravljenja HIV« v poglavju 4 tega navodila.
English: § Includes reasons such as withdrew consent, loss to follow-up, protocol deviation.
Slovenian: § Vključuje razloge, kot so umik soglasja, prenehanje spremljanja, odstopanje od protokola.
English: • trimethoprim/sulfamethoxazole, an antibiotic to treat bacterial infections
Slovenian: • trimetoprim/sulfametoksazol, antibiotik za zdravljenje bakterijskih okužb
English: Patients with this gene are at a high risk of developing a serious hypersensitivity (allergic) reaction if they use Triumeq (see ‘hypersensitivity reactions' in section 4).
Slovenian: Pri bolnikih s tem genom obstaja visoko tveganje za razvoj hude preobčutljivostne (alergijske) reakcije, če uporabljajo zdravilo Triumeq (glejte »Preobčutljivostne reakcije« v poglavju 4).
English: If ABC hypersensitivity cannot be ruled out on clinical grounds, ABC should be permanently discontinued and should not be restarted, regardless of the results of HLA-B*5701 screening.
Slovenian: Če se na podlagi kliničnih podatkov preobčutljivosti za ABC ne da izključiti, je treba zdravljenje z ABC za vedno prekiniti in se ga ne sme nikoli več ponovno uvesti, ne glede na rezultate presejanja za HLA-B*5701.
English: Children and adolescents aged between 12 and 17 years and weighing at least 40 kg can take the adult dose of one tablet once a day.
Slovenian: Otroci in mladostniki, stari med 12 in 17 let, ki tehtajo vsaj 40 kg, lahko dobijo odmerek za odrasle, eno tableto enkrat dnevno.
English: The analyses included two randomized, international, double-blind, activecontrolled trials, SINGLE (ING114467) and SPRING-2 (ING113086), the international, open-label, active-controlled trial FLAMINGO (ING114915), and the randomized, open-label, active-controlled, multicentre, non-inferiority study ARIA (ING117172).
Slovenian: Analize so obsegale dve randomizirani, mednarodni, dvojno slepi, z zdravilno učinkovino nadzorovani študiji SINGLE (ING114467) in SPRING-2 (ING113086); mednarodno, odprto, z zdravilno učinkovino nadzorovano študijo FLAMINGO (ING114915) in randomizirano, odprto, z zdravilno učinkovino nadzorovano multicentrično študijo neinferiornosti ARIA (ING117172).
English: Resistance in vitro: (dolutegravir)
Slovenian: Odpornost in vitro: (dolutegravir)
English: For the comparators typical resistance was detected with TDF/FTC/EFV (SINGLE; six with NNRTI associated resistance and one with major NRTI resistance) and with 2 NRTIs + raltegravir (SPRING2; four with major NRTI resistance and one with raltegravir resistance), while no de novo resistance was detected in patients treated with 2 NRTIs + DRV/RTV (FLAMINGO).
Slovenian: Za primerjavo, tipična odpornost je bila ugotovljena pri TDF/FTC/EFV (SINGLE; pri šestih odpornost na NNRTI, pri enem pa glavna odpornost na NRTI) in pri 2 NRTIs + raltegravir (SPRING2; pri štirih glavna odpornost na NRTI in pri enem odpornost na raltegravir), medtem ko pri bolnikih, zdravljenih z 2 NRTIs + DRV/RTV (FLAMINGO), niso odkrili nobene na novo nastale odpornosti.
English: Poly(vinyl) alcohol - partially hydrolysed titanium dioxide macrogol talc iron oxide black iron oxide red
Slovenian: Obloga tablete poli(vinil) alkohol - delno hidroliziran titanov dioksid makrogol smukec črni železov oksid rdeči železov oksid
English: Interactions between dolutegravir, abacavir, lamivudine and co-administered medical products are listed in Table 1 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, area under the concentration versus time curve as “AUC”, maximum observed concentration as “Cmax”).
Slovenian: Interakcije med dolutegravirjem, abakavirjem, lamivudinom in sočasno uporabljenimi zdravili so navedene v Preglednici 1 (zvečanje je označeno kot “↑” , zmanjšanje kot “↓” , brez spremembe kot “↔” , površina pod koncentracijsko krivuljo v odvisnosti od časa kot “AUC”, maksimalna zabeležena koncentracija pa kot “Cmax”).
English: • muscle pain and discomfort
Slovenian: • bolečine v mišicah in nelagodje